Can Orex make money selling so cheap and probably very limited sales noting that the drugs have such significant side effects? If people stop taking Belviq because of a slight headache I'm pretty sure that Contrave causing nausea will stop sooner. Anyone know the cost to manufacture Contrave? Maybe why the street is not impressed thus low share price.
Sentiment: Strong Buy
Well the board has been saying this for 2 years and the PPS has gone down from 9 to 3.36? Shorts doubled down with another 5 million shares at the latest settlement. I think any investor would be thinking do they know something longs don't? I mean it not like they have it wrong they are the ones making money and longs are losing.. Hope your right but doubt it based on what has happened over the past 2 yrs. ya I know , phen smoking an other patents but it's had NO effect on PPS
CEO dumps shares at $5.85, then buys more at $2.49? Then collects $5 million dollar bonus? hahahaha
SSRI Pain Management has been at issue for a while now. But it is prescribed off Label. If APD371 is approved EXCLUSIVELY for Pain Management then who knows what will happen to Arena Pharma.
Psychiatry (Edgmont). Dec 2008; 5(12): 16–19.
Published online Dec 2008.
Neuropathic pain is a relatively common clinical entity. Given the current diversity of available antidepressant options, many different types appear to be efficacious in the treatment of pain, with the exception of SSRIs. Hopefully, future studies will clarify the genuine role of neurotransmitters in pain modulation as well as the explicit comparative efficacies of the available antidepressants. In addition to their effects on pain, future studies may also take into consideration the effect of antidepressants on the overall quality of life and functioning. It seems clear that antidepressants have an important role in the treatment of neuropathic pain—an observation that is highly relevant for both psychiatrists and primary care clinicians.
900 sales reps " with samples in hand" at the start vs 200 at the start for belcebo
Takeda has launched Contrave with a "Direct Save" option that utilizes home delivery of the medicine. For patients with insurance the cost of Contrave will be $55 per month for the first two months and then $45 per month thereafter provided that the patient does not miss a refill. For consumers without an anti-obesity benefit, the cost will be $70 per month for the first two months and $60 for month three and beyond.
This unique program accomplishes two things. First, it brings the price point down to a level that consumers may be able to stomach more-so than the $200 per month price tag before coupons and rebates. Second, it helps guarantee that once on the drug, consumers will refill.
agree, cost could take some market share. Bel needs Phen. They might need to try the 1 Bel/day + phen approach to keep costs low, which would mean they will have to find 2x patients to stay even. Smoking better be positive, or we could be in for a long slog period of slow growth, cost cutting and losses.
and people say bababara's not a PUMPER....Here's one in yer ear babs (P.S: you DO know what the word "tangential" means, don't you????) LOL
iBio , for example, has jumped almost seven-fold since early September on speculation that the tktk-based company's plant-based antibody manufacturing technology would play a big part in ramping up production of ZMapp, the experimental Ebola drug used to treat several infected patients already before supplies ran out. The truth is more sobering: iBio is a tangential player in one of several ZMapp manufacturing plans under consideration. The odds of iBio generating meaningful revenue from ZMapp are small relative to the company's almost $200 million market value.
IBIO now trading at $1.77 on volume pre market. Glad you hung on babs. Couldn't happen to a more miserable guy. Next stop a buck. Articles out this morning that ebola related stocks highly overpriced. bwaaaahahahahah bagholder.
Here is the link to Jon's interview (comments begin at 11:05 on ARNA):
Jon did say OTC for weight loss drug and looking for new approvals. Listen to the podcast.